References
- Bjornsti M A, Houghton P J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335–348
- Altman J K, Platanias L C. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008; 15: 88–94
- Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416–6422
- Platanias L C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375–386
- Schmelzle T, Hall M N. TOR, a central controller of cell growth. Cell 2000; 103: 253–262
- Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926–1945
- Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8: 63–87
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–2281
- Witzig T E, Geyer S M, Ghobrial I, Inwards D J, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347–5356
- Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November. J Clin Oncol 1999; 17: 3835–3849
- Hotta T. Treatment of T-cell lymphoma. Hematology 2005; 10: 193–196
- Hirase C, Maeda Y, Yamaguchi T, Miyatake J-I, Kanamaru A. mTOR inhibition and adult T-cell leukemia. Leuk Lymphoma 2009; 50: 645–647